These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19698801)

  • 1. Challenges and perspectives in vaccination against leishmaniasis.
    de Oliveira CI; Nascimento IP; Barral A; Soto M; Barral-Netto M
    Parasitol Int; 2009 Dec; 58(4):319-24. PubMed ID: 19698801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines in leishmaniasis: advances in the last five years.
    Brodskyn C; de Oliveira CI; Barral A; Barral-Netto M
    Expert Rev Vaccines; 2003 Oct; 2(5):705-17. PubMed ID: 14711330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
    Tonui WK; Titus RG
    Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
    Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
    Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of sand fly saliva in human and experimental leishmaniasis: current insights.
    Andrade BB; de Oliveira CI; Brodskyn CI; Barral A; Barral-Netto M
    Scand J Immunol; 2007; 66(2-3):122-7. PubMed ID: 17635789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen.
    Masina S; M Gicheru M; Demotz SO; Fasel NJ
    J Infect Dis; 2003 Oct; 188(8):1250-7. PubMed ID: 14551897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Researchers home in on leishmaniasis vaccine.
    Am J Vet Res; 2001 Oct; 62(10):1517. PubMed ID: 11592312
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
    Rafati S; Ghaemimanesh F; Zahedifard F
    Vaccine; 2006 Apr; 24(16):3290-7. PubMed ID: 16481076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania.
    Al-Wabel MA; Tonui WK; Cui L; Martin SK; Titus RG
    Am J Trop Med Hyg; 2007 Dec; 77(6):1060-5. PubMed ID: 18165522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sand fly saliva: effects on host immune response and Leishmania transmission.
    Rohousová I; Volf P
    Folia Parasitol (Praha); 2006 Sep; 53(3):161-71. PubMed ID: 17120496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunity to Lutzomyia whitmani Saliva Protects against Experimental Leishmania braziliensis Infection.
    Gomes R; Cavalcanti K; Teixeira C; Carvalho AM; Mattos PS; Cristal JR; Muniz AC; Miranda JC; de Oliveira CI; Barral A
    PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005078. PubMed ID: 27812113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis.
    Calvopina M; Barroso PA; Marco JD; Korenaga M; Cooper PJ; Nonaka S; Hashiguchi Y
    Vaccine; 2006 Jul; 24(27-28):5645-52. PubMed ID: 16621179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infectious diseases. Sand fly saliva may be key to new vaccine.
    Enserink M
    Science; 2001 Aug; 293(5532):1028. PubMed ID: 11498553
    [No Abstract]   [Full Text] [Related]  

  • 17. Recombinant DNA-derived leishmania proteins: from the laboratory to the field.
    Kubar J; Fragaki K
    Lancet Infect Dis; 2005 Feb; 5(2):107-14. PubMed ID: 15680780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current approaches to improving vaccination against zoonotic cutaneous leishmaniasis (the international experience)].
    Gafurov IM
    Med Parazitol (Mosk); 1998; (4):47-8. PubMed ID: 10050557
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunization with LJM11 salivary protein protects against infection with Leishmania braziliensis in the presence of Lutzomyia longipalpis saliva.
    Cunha JM; Abbehusen M; Suarez M; Valenzuela J; Teixeira CR; Brodskyn CI
    Acta Trop; 2018 Jan; 177():164-170. PubMed ID: 29037520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.